par Staquet, Maurice 
;Rozencweig, Marcel ;Von Hoff, Daniel D.D.;Muggia, Franco F.M.
Référence Cancer treatment reports, 63, 11-12, page (1917-1921)
Publication Publié, 1979
;Rozencweig, Marcel ;Von Hoff, Daniel D.D.;Muggia, Franco F.M.Référence Cancer treatment reports, 63, 11-12, page (1917-1921)
Publication Publié, 1979
Article révisé par les pairs
| Résumé : | The error probabilities α and β are widely used to compute sample sizes and to analyze results of clinical trials. These errors are, however, not the only probablities to consider when assessing results of clinical studies. The rate of false positive (δ) and false negative (ε) results allows one to determine if an experimental finding is likely to reflect the true situation in the population of interest. The δ error is generally high in randomized phase III and in early phase II clinical trials in cancer patients, whereas the ε error is relatively low in these settings. This is essentially due to the small probability of detecting a more effective treatment or a new chemotherapeutic agent active in cancer. The δ error could be considerably reduced by increasing the sample sizes and by restricting the allowance made for the α error, which should be set at a 1% level as a minimum requirement. |
